Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 3755 Côte Ste-Catherine Road, Montreal, Quebec H3T 1E2, Canada.
Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Purvis Hall, 1020 Pine Avenue West, Montreal, Quebec H3A 1A2, Canada.
Nat Rev Clin Oncol. 2017 Feb;14(2):85-99. doi: 10.1038/nrclinonc.2016.120. Epub 2016 Aug 9.
The prevalence of obesity, of type 2 diabetes mellitus (T2DM), and of cancer are all increasing globally. The relationships between these diseases are complex, and thus difficult to elucidate; nevertheless, evidence supports the hypothesis that obesity increases the risks of both T2DM and certain cancers. Further complexity arises from controversial evidence that specific drugs used in the treatment of T2DM increase or decrease cancer risk or influence cancer prognosis. Herein, we review the current evidence from studies that have addressed these relationships, and summarize the methodological challenges that are frequently encountered in such research. We also outline the physiology that links obesity, T2DM, and neoplasia. Finally, we outline the practical principles relevant to the increasingly common challenge of managing patients who have been diagnosed with both diabetes and cancer.
肥胖、2 型糖尿病(T2DM)和癌症的患病率在全球范围内都呈上升趋势。这些疾病之间的关系很复杂,因此难以阐明;然而,有证据支持肥胖会增加 T2DM 和某些癌症风险的假设。进一步的复杂性来自于有争议的证据,即用于治疗 T2DM 的特定药物会增加或降低癌症风险或影响癌症预后。本文综述了目前研究这些关系的证据,并总结了此类研究中经常遇到的方法学挑战。我们还概述了将肥胖、T2DM 和肿瘤联系起来的生理学。最后,我们概述了与越来越常见的同时患有糖尿病和癌症的患者的管理相关的实际原则。